Mer­ck­'s LAG-3 plus Keytru­da com­bo fails Phase 3 in col­orec­tal can­cer

Mer­ck’s ef­forts to com­bine its PD-1 block­buster Keytru­da with an ex­per­i­men­tal LAG-3 in­hibitor hit a stum­bling block Wednes­day morn­ing.

The com­pa­ny said a Phase 3 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER